.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Fish and Richardson
Citi
Argus Health
UBS
Cerilliant
Federal Trade Commission
Healthtrust
McKesson
Baxter

Generated: December 16, 2017

DrugPatentWatch Database Preview

PLENAXIS Drug Profile

« Back to Dashboard

Summary for PLENAXIS

Drug patent expirations by year for PLENAXIS

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Speciality EuropeanPLENAXISabarelixINJECTABLE;INTRAMUSCULAR021320-001Nov 25, 2003DISCNNoNo► Subscribe► SubscribeY► Subscribe
Speciality EuropeanPLENAXISabarelixINJECTABLE;INTRAMUSCULAR021320-001Nov 25, 2003DISCNNoNo► Subscribe► SubscribeY► Subscribe
Speciality EuropeanPLENAXISabarelixINJECTABLE;INTRAMUSCULAR021320-001Nov 25, 2003DISCNNoNo► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: PLENAXIS

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Speciality EuropeanPLENAXISabarelixINJECTABLE;INTRAMUSCULAR021320-001Nov 25, 2003► Subscribe► Subscribe
Speciality EuropeanPLENAXISabarelixINJECTABLE;INTRAMUSCULAR021320-001Nov 25, 2003► Subscribe► Subscribe
Speciality EuropeanPLENAXISabarelixINJECTABLE;INTRAMUSCULAR021320-001Nov 25, 2003► Subscribe► Subscribe
Speciality EuropeanPLENAXISabarelixINJECTABLE;INTRAMUSCULAR021320-001Nov 25, 2003► Subscribe► Subscribe
Speciality EuropeanPLENAXISabarelixINJECTABLE;INTRAMUSCULAR021320-001Nov 25, 2003► Subscribe► Subscribe
Speciality EuropeanPLENAXISabarelixINJECTABLE;INTRAMUSCULAR021320-001Nov 25, 2003► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Premature patent expiration for: PLENAXIS

Expiration due to failure to pay maintenance fee

Patent Number Tradename Expiration Date
► Subscribe PLENAXIS ► Subscribe

International Patent Family for Tradename: PLENAXIS

Country Document Number Estimated Expiration
Australia7822801► Subscribe
Brazil9714015► Subscribe
Australia779930► Subscribe
New Zealand579443► Subscribe
Australia735174► Subscribe
Canada2274847► Subscribe
Australia5699198► Subscribe
Turkey9901382► Subscribe
European Patent Office1878437► Subscribe
Portugal952843► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: PLENAXIS

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2011 00004Denmark► SubscribePRODUCT NAME: ABARELIX, EVENTUELT I FORM AF ET FARMACEUTISK SALT; NAT. REG. NO/DATE: 44637 (DK) 20100827; FIRST REG. NO/DATE: DE 578900000 20050922
C0015France► SubscribePRODUCT NAME: ABARELIX, EVENTUELLEMENT SOUS FORME DE SEL PHARMACEUTIQUEMENT ACCEPTABLE; REGISTRATION NO/DATE IN FRANCE: 69026150 DU 20101126; REGISTRATION NO/DATE AT EEC: 57890.00.00 DU 20050922
90014-9Sweden► SubscribePRODUCT NAME: ABARELIX
00484Netherlands► SubscribePRODUCT NAME: ABARELIX, EVENTUEEL IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; NAT. REGISTRATION NO/DATE: RVG 104389 20101220; FIRST REGISTRATION: 57890.00.00 20050922
C/GB11/006United Kingdom► SubscribePRODUCT NAME: ABARELIX, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: DE - 20050922; UK PL32828/001 20100917
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Farmers Insurance
Queensland Health
Johnson and Johnson
Dow
Moodys
Express Scripts
Merck
Colorcon
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot